Evidence map›Paper›PMID 40090719›Full record

ArticleInternal medicine (Tokyo, Japan)2025

A Severe Case of Rhabdomyolysis Requiring Renal Replacement Therapy Following COVID-19 mRNA Vaccination.

Motohiro Ueda, Kohei Uchimura, Kie Ohkoshi, Natsumi Saegusa, Keiichi Osano, Shun Yoshida, Makiko Konishi, Toshihisa Ishii, Kazuya Takahashi, Ayumu Nakashima

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Motohiro UedaDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Kohei UchimuraDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Kie OhkoshiDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Natsumi SaegusaDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Keiichi OsanoDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Shun YoshidaDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Makiko KonishiDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Toshihisa IshiiDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Kazuya TakahashiDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Ayumu NakashimaDepartment of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old man who developed rhabdomyolysis and severe acute kidney injury (AKI) after the fourth coronavirus disease 2019 mRNA vaccination, necessitating renal replacement therapy (RRT). The patient presented to the hospital two days post-vaccination with muscle pain in both lower extremities and anuria. Diagnostic tests revealed elevated creatinine kinase (CK) levels of 160,000 IU/L and serum creatinine levels of 6.59 mg/dL, confirming AKI due to rhabdomyolysis. Intravenous therapy was ineffective, leading to the utilization of online hemodiafiltration. Following treatment, CK levels normalized, and the renal function fully recovered.

Indexed as

Acute Kidney InjuryCOVID-19COVID-19 VaccinesRenal Replacement TherapyRhabdomyolysisVaccinationCreatine KinaseHemodiafiltrationHumansMaleMiddle AgedSARS-CoV-2COVID-19 VaccinesCreatine Kinaseacute kidney injuryCOVID-19mRNA vaccineonline hemodiafiltrationrhabdomyolysisstatin

Identifiers

PMID40090719
PMCPMC12183419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.